Highest-materiality recent filing
Iridex Q2 revenue down 7% to $12.6M; glaucoma G6 up 19%, retina weak
Total revenue $12.6M, down 7% YoY; net loss $1.3M ($0.07/share) vs $1.0M loss prior year.
Iridex alleges stealth proxy campaign by Novel; Novel discloses 39% stake after belated 13D filing
All five director nominees elected despite 'withhold' campaign targeting Huss and Shuda; plurality standard applied.
Iridex Q4 revenue $14.7M up 16% YoY; first positive adjusted EBITDA
Q4 total revenue $14.7M (+16% YoY); retina $8.9M (+22%), Cyclo G6 $3.8M (+15%).
Iridex Q4 2025 revenue up 15-17% YoY to ~$14.7M; positive cash flow in quarter
Q4 2025 revenue expected $14.6-14.8M vs $12.7M prior year, +15-17% YoY.
Iridex Q3 revenue $12.5M (+8% YoY); expects positive adjusted EBITDA in FY2025
Total revenue $12.5M (+8% YoY); Cyclo G6 revenue $3.5M (+13%); Retina revenue $6.7M (+4%).
Revenue $13.6M, up 7% YoY and 14% sequential; retina product revenue $8.0M (+10% YoY).
IRIDEX stockholders approve doubling authorized shares to 63.5M and 1M share increase in equity plan
Authorized common stock increased from 30M to 63.5M shares; Restated Charter effective June 11, 2025.
IRIDEX receives Nasdaq delisting notice; equity only $852K vs $2.5M minimum; seeks shareholder vote
Stockholders' equity was ~$852,000 as of March 29, 2025, below Nasdaq's $2.5M minimum.
Iridex Q1 revenue $11.9M, positive adj EBITDA $0.4M after $10M strategic investment
Total revenue $11.9M (flat YoY); Cyclo G6 glaucoma revenue up 8% to $3.2M; Retina revenue down 3% to $6.6M.
IRIDEX director Robert E. Grove resigns effective April 2, 2025 per Novel transaction agreement
Robert E. Grove resigned from the Board and all committees effective April 2, 2025.
Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M
Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.
IRIDEX raises $10M via preferred stock and convertible note; repays Lind debt; new CFO and directors
Issued 600K Series B Preferred at $10/sh (convertible into 3M common) and $4M 12% convertible note to Novel Inspiration.
Iridex Q4 revenue $12.6-12.7M, flat YoY; FY 2024 revenue $48.6-48.7M, down 6%
Q4 revenue expected $12.6-12.7M vs $12.5M in prior year; sold 47 Cyclo G6 systems (vs 35).
IRIDEX corrects CEO Bruce's resignation date; details severance and Mercer's CEO comp
David Bruce terminated as CEO Oct 1, resigned board Nov 22, 2024; no disagreement with company policies.
IRIDEX CEO David Bruce terminated; Patrick Mercer takes over as CEO effective Nov 7, 2024
David Bruce terminated as CEO Oct 1, 2024, resigned from Board Nov 11, 2024; receives $45K cash and acceleration of 19,913 RSUs and 40,431 options.
Iridex Q3 revenue $11.6M (-10% YoY); net loss $1.9M; expects EBITDA breakeven in Q4
Total revenue $11.6M, down 10% YoY; retina revenue $6.5M (-18% YoY).
Iridex appoints Patrick Mercer as CEO; strategic review for potential transaction ongoing
Patrick Mercer named CEO and President effective Oct 1, 2024; previously COO and President.
IRIDEX files S-3 to register resale of up to ~1.7M shares from $4.2M convertible note
Filed registration statement for resale of shares issuable upon conversion of $4.2M senior convertible note to Lind Global.
Iridex Q2 revenue flat at $12.6M; net loss $2.7M; raises $3.4M via convertible note
Q2 revenue $12.6M, flat YoY; net loss $2.7M ($0.16 EPS) vs $2.8M loss in prior year.
Iridex secures $3.5M convertible note from Lind; potential $1.5M add-on
Net proceeds ~$3.5M from $4.2M principal senior convertible note to Lind; $1.5M additional note available.
IRIDEX receives Nasdaq notice for MVLS below $50M; plans transfer to Capital Market
On June 27, 2024, Nasdaq notified IRIX that its market value of listed securities was below $50M for 30 consecutive business days.
IRIDEX appoints Patrick Mercer as President; CEO focuses on strategic alternatives
Patrick Mercer appointed President, effective May 22, 2024; remains COO with expanded operational focus.
Iridex Q1 revenue down 14% to $11.8M; net loss widens; strategic review ongoing after deal collapse
Q1 revenue $11.8M vs $13.7M YoY; net loss $3.5M ($0.21/share) vs $2.1M ($0.13/share).
Iridex reports Q4 2023 revenue of $12.5M, net loss of $3.0M; full-year revenue down 9%
Q4 2023 total revenue $12.5M vs $15.2M YoY; net loss $3.0M ($0.18 per share) vs $1.1M loss in Q4 2022.
Iridex wins broader Medicare coverage for cyclophotocoagulation after LCD appeal
Five Medicare Administrative Contractors corrected CPC coverage criteria; 'AND' changed to 'OR', broadening patient access.
Iridex Q3 revenue $12.9M (-12% YoY); five MACs restrict glaucoma reimbursement; guidance withdrawn
Q3 revenue $12.9M, down 12% YoY; net loss $1.8M ($0.11/share) flat vs prior year.
Delaware Court validates IRIDEX's amended charter; all corporate actions deemed effective
Delaware Court of Chancery granted Section 205 petition on Nov 1, 2023, validating IRIDEX's Amended and Restated Certificate of Incorporation filed Feb 22, 1996.
IRIDEX withdraws FY2023 guidance after Medicare LCD restricts glaucoma reimbursement
WPS Medicare LCD effective Dec 24, 2023 will likely limit cyclophotocoagulation coverage to only refractory glaucoma patients meeting strict criteria.
IRIDEX Q2 revenue down 7% to $12.9M; net loss widens; FY2023 guidance narrowed
Q2 revenue $12.9M, -7% YoY; Cyclo G6 product revenue up 5% to $3.7M.
Stockholders approved 1,000,000 share increase to 2008 Equity Incentive Plan (5.4M for, 1.1M against).
Iridex Q4 revenue flat at $15.2M; record glaucoma probe sales; FY net loss widens to $7.5M
Q4 revenue $15.2M (flat YoY); net loss improved to $1.1M ($0.07/sh) from $2.4M loss.
Iridex reports flat Q4 revenue, record Cyclo G6 probe sales; FY revenue up 6%
Q4 revenue expected $15.1-15.3M, flat YoY; FY revenue $56.9-57.1M, up 6% from $53.9M in 2021.
IRIDEX reports record Q3 revenue $14.6M, net loss narrows to $1.8M; maintains FY guidance
Total revenue $14.6M, +10% YoY, record Q3; net loss $1.8M ($0.11/share) vs $2.2M loss ($0.14) prior year.
Iridex Q2 revenue $13.8M (+2% YoY); net loss $2.2M; lowers FY22 guidance
Total revenue $13.8M, up 2% YoY; net loss $2.2M ($0.14/sh) vs net income $1.4M ($0.09) prior year due to one-time PPP loan forgiveness.
Iridex Q1 revenue $13.4M (record), up 12% YoY; net loss $2.4M; guides FY22 rev $57-59M
Record Q1 revenue $13.4M (+12% YoY); net loss $2.4M ($0.15/sh) vs $2.0M ($0.14/sh) prior year.
Kenneth E. Ludlum has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 7, 2025.
Robert E. Grove has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 2, 2025.
Romeo Dizon was appointed by the Company’s Board as its Chief Financial Officer, to replace Fuad Ahmad effective as of the Closing
the Company’s board of directors (the “Board”) appointed William Moore and Nick Chen as members of the Board, effective as of the Closing
the Company’s board of directors (the “Board”) appointed William Moore and Nick Chen as members of the Board, effective as of the Closing
Romeo Dizon was appointed by the Company’s Board as its Chief Financial Officer, to replace Fuad Ahmad effective as of the Closing
On November 22, 2024, the board of directors (the “Board”) of IRIDEX Corporation (the “Company”) appointed Patrick Mercer, the Company’s current President, Chief Executive Officer and Chief Operating Officer, to serve as a member of the Board, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, effective immediately.
On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer and principal executive officer, effective immediately, and on November 22, 2024, Mr. Bruce resigned from the Board, effective immediately.
on November 22, 2024, Mr. Bruce resigned from the Board, effective immediately.
on November 11, 2024, Mr. Bruce resigned from the Board.
On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer (the “CEO”) and principal executive officer, effective immediately
replacing David I. Bruce in such roles
Max materiality 0.85 · Median 0.60 · Most common event earnings